- Global Pharma News & Resources

Medigene AG: New safety data shows Medigene's inducible system produces correctly-paired T cell receptors only

Medigene AG: New safety data shows Medigene's inducible system produces correctly-paired T cell receptors only

Poster presentation at the ESMO Immuno-Oncology Congress

Planegg/Martinsried (pta/08.12.2021/08:30) Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, will present new safety data showing that its inducible Medigene T cell receptor (iM-TCR) system produces only correctly-paired T cell receptors (TCRs). The data will be presented from today at the ESMO Immuno-Oncology Congress, taking place both virtually and on-site in Geneva, Switzerland, from 8-11 December 2021.

Medigene's inducible TCR (iM-TCR) - A fine control system to switch TCR-T cells on and off

The iM-TCR system controls the level of expression of an introduced TCR on the surface of T cells, thereby governing the amount of functional activity of the TCR-T cells on the cell surface. In the presence of the appropriate drug the two chains of the TCR pair and the TCR is brought onto the T cell surface; without the drug, they disappear and new TCRs are only replaced upon new specific drug induction. The presence or absence of the drug therefore determines the level of activity of the TCR-T cells, potentially allowing clinicians to switch TCR-T activity on or off as required.

Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene: "T cell receptors consist of two different chains, alpha and beta. It was possible that non-specific "forced" pairing - triggered by the administration of a certain drug - would produce unwanted alpha-alpha or beta-beta pairs in addition to the intended alpha-beta pairs. This would have posed a safety risk, since TCRs with new and unknown reactivities could thus arise. However, our experiments have ruled this out: in an in vitro system we have shown that only the desired alpha-beta pairs are formed.

This is another important step in ensuring the safety and functionality of modified T cells for transfer into patients and to allow first clinical testing. Our iM-TCR system is designed to enable physicians to avoid unwanted side effects of TCR-T therapy and to regulate an ongoing immune response precisely."

Editor Details

Last Updated: 09-Dec-2021